Clinical trials: Hepatic Neoplasm
Hepatocellular Carcinoma
cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
This study will evaluate the efficacy and safety of Sintilimab plus Transcatheter arterial chemoembolization (TACE) in participants with Intermediate-stage unresectable hepatocellular carcinoma with Beyond Up-to-seven Criteria.
- Trial name
- NCT04842565
- Testing
- Sintilimab, TACE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma
ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor…
- Conditions
- Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Liver Cancer
- Trial name
- NCT06326502
- Testing
- ETN101
- Where
- 2 sites in South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Etnova Therapeutics Corp.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Liver Cancer, Surgery
Hepatocarcinoma Recurrence on the Liver Study - Part2
Rationale for the trial. To evaluate the impact of surgery on hepatocarcinoma recurrence. Thus, to evaluate the impact of different clinical, radiological, histopathological variables on recurrence after surgical treatment.
- Conditions
- Liver Cancer, Surgery, Recurrence Tumor, Cirrhosis
- Trial name
- HERCOLES2 (NCT04053231)
- Testing
- liver resection
- Where
- 19 sites in Italy
- Volunteers
- 3,000 people
- Sponsor
- University of Milano Bicocca
Hepatocellular Carcinoma
Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma
Transfemoral Versus Transradial Approach in Transarterial Chemoembolization of Hepatocellular Carcinoma
- Trial name
- NCT06543030
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Colorectal Cancer, Hepatic Metastases
Evaluation of 2 Resection Strategies of Synchronous Colorectal Cancer Metastases
The surgical strategy for the treatment of synchronous colorectal cancer liver metastases has not still been defined. The purpose of this study is to compare two treatment strategies in which liver resection is performed either…
- Trial name
- METASYNC (NCT00264979)
- Testing
- Simultaneous surgery, Sequential surgery
- Where
- 14 sites in France
- Volunteers
- 105 people
- Sponsor
- Rennes University Hospital
Bladder Carcinoma, Gastric Carcinoma
Patient-Derived Xenografts to Reduce Cancer Health Disparities
This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities.
- Conditions
- Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma
- Trial name
- NCT04410302
- Testing
- Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of California, Davis
Liver Cancer
Microarray Analysis of Gene Expression in Liver Tumors
This study aims to study the gene expression profiles of liver tumors to help us understand their biology, and to find new tumor and treatment markers for liver cancer.
- Trial name
- NCT00373737
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Stanford University
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
This phase I/II trial studies the side effects and how well nivolumab, fluorouracil, and interferon alpha 2b work for the treatment of fibrolamellar cancer (liver cell cancer) that cannot be removed by surgery (unresectable).
- Conditions
- Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04380545
- Testing
- Fluorouracil, Nivolumab, Recombinant Interferon Alpha 2b-like Protein
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
A Real World Study of Regogfinib in HCC
This is a non-interventional observational study with the primary objective of assessing the efficacy of regorafenib in patients with immediate or advanced stage HCC.
- Trial name
- NCT05557656
- Testing
- Regorafenib 40 MG
- Volunteers
- 800 people
- Sponsor
- Zhongda Hospital
Liver Cancer
Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma
To evaluate whether tracking changes in key blood markers over time, together with clinical features, can improve the prediction of outcomes in patients with hepatocellular carcinoma (HCC).
- Trial name
- NCT07204262
- Testing
- Molecular Targeted Therapy (TKI / anti-VEGF antibody) PD-(L)1 Inhibitor Immunotherapy Interventional Therapy (TACE / HAIC)
- Where
- China
- Volunteers
- 379 people
- Sponsor
- Xu Yong, MD
Hepatocellular Carcinoma, Cirrhosis
Evaluation of Proteasome as a Marker of Hepatocellular Carcinoma in Cirrhotic Patients Following Curative Treatment
This study will evaluate the usefulness of plasma proteasome levels as a tumor marker of hepatocellular carcinoma (HCC) by studying their variation following curative treatment of HCC.
- Trial name
- NCT01492127
- Testing
- Blood test
- Where
- France
- Volunteers
- 64 people
- Sponsor
- University Hospital, Montpellier
Hepatobiliary Cancer, Pancreatic Cancer
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies…
- Conditions
- Hepatobiliary Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT05497531
- Testing
- ctDNA Blood Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Irvine
Hepatocellular Carcinoma, Hepatocellular Cancer
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
Background: A new cancer treatment takes a person s own T cells, modifies them in a laboratory so they can better fight cancer cells, and then gives them back to the person.
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05003895
- Testing
- Cyclophosphamide, CAR-T cell, Fludarabine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Hepatocellular Carcinoma, HCC
Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)
This single arm, open label, two stage study will be conducted in several medical centers around Taiwan. Stage one determine safety and tolerability in patients with HCC, and stage two assess anti-tumor activities of GT90001 in…
- Conditions
- Metastatic Hepatocellular Carcinoma, HCC, Combinations of Drugs; Dependence
- Trial name
- NCT03893695
- Testing
- GT90001 and Nivolumab
- Where
- 3 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Intrahepatic Cholangiocarcinoma
A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC
Southeast Asia and China have the highest incidence of intrahepatic cholangiocarcinoma worldwide, with limited treatment options and large unmet medical needs.
- Trial name
- NCT06375642
- Testing
- Adebrelimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
HCC - Hepatocellular Carcinoma
Measuring the Density of Iodine in Lipiodol Depositions: Detecting an Invisible Residual Tumor After Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma
ABSTRACT Objective: To detect presence of a residual tumor in patients of hepatocellular carcinoma (HCC) treated with Lipiodol based conventional trans arterial chemoembolization (cTACE) using density measurements on follow-up…
- Trial name
- NCT06602986
- Testing
- TACE
- Where
- Pakistan
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Pak Emirates Military Hospital
Hepatocellular Carcinoma
A Study of PTS100 in Primary HCC Patients
This study is being performed to evaluate the efficacy and safety of 30% PTS100 of total tumor volume as intra-tumoral injection therapy in primary Hepatocellular Carcinoma patients who are ineligible for operation or local…
- Trial name
- OASES (NCT03447951)
- Testing
- Para-Toluenesulfonamide
- Where
- 3 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Gongwin Biopharm Co., Ltd.
Radiology, Interventional, Liver Neoplasm
Biliary or Digestive Protection by Room Air Interposition for Thermal Ablation of Central Hepatic Tumors
This study aims to analyse retrospectively the feasibility, the safety, and the efficiency, of biliary or digestive protection with room air interposition for thermal ablation of central liver tumors with high iatrogenic risk.
- Conditions
- Radiology, Interventional, Liver Neoplasm, Carcinoma, Hepatocellular (RENI), Neoplasm Metastasis
- Trial name
- NCT05495529
- Testing
- Thermal Ablation
- Where
- France
- Volunteers
- 61 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.